Chemical Structure (Risedronate Sodium Delayed Release Tablets 1)
Risedronate Sodium
Product Images NDC 0115-1426
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 3 technical images submitted to the FDA as part of the official labeling for Risedronate Sodium (NDC 0115-1426). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Impax Generics, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Figure 1 (Risedronate Sodium Delayed Release Tablets 2)
This is a graph (Figure 1) showing the percentage of patients who developed nonvertebral fractures related to osteoporosis over a period of 3 years. The graph includes data from two studies: VERT MN and VERT NA. There are six different types of fractures shown (wrist, humerus, hip, pelvis, leg, and clavicle) and two treatment options (placebo and ACTONEL 5mg).*
Carton (Risedronate Sodium Delayed Release Tablets 3)
This is a medication guide for Risedronate Sodium Delayed-Release Tablets, with a strength of 35 mg, to be taken once a week on the same day every week. The tablets must be swallowed whole immediately after breakfast with at least 2 ounces of plain water. The patient should not lie down for at least 30 minutes, chew, cut or crush the tablet. Calcium supplements, antacids, magnesium-based supplements, laxatives, and iron preparations should not be taken at the same time of the day. The NDC code is 0115142634.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
